[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aspergillosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aspergillosis":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100349358","ptx3-targeted-antifungal-prophylaxis-100349358",false,"NCT03828773","PTX3-targeted Antifungal Prophylaxis","PTX3 Genetically Stratified Randomized Double-blinded Allocation Event-driven Clinical Trial for Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia","PTX3AML","Inclusion Criteria:\n\n1. Signed Informed Consent according to national\u002Flocal regulations.\n2. Age ≥18 years.\n3. Diagnosis of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome in transformation (MDSit) treated with an intensive chemotherapy regimen, including induction \u002F consolidation \u002F salvage remission chemotherapy.\n4. Planned hospital admission for the duration of the neutropenic phase (absolute neutrophils count \\\u003C500 cells\u002Fmm3).\n\nExclusion Criteria:\n\n1. Patients with neutropenia (absolute neutrophils count\\\u003C500 cells\u002Fmm3) upon presentation and prior to chemotherapy initiation.\n2. Patients with a diagnosis of acute promyelocytic leukemia (APL) or AML-M3.\n3. Patients with known history of allergy, hypersensitivity or serious reaction to azole antifungals\n4. Women who are pregnant (positive blood\u002Furine pregnancy test within 10 days before randomization) or breast-feeding.\n5. Diagnosis and treatment for an Invasive Fungal Infection (IFI) within 3 months prior to study enrolment and an Invasive Mold Infection (IMI) at any point prior to or at the time of enrolment.\n6. Severe liver dysfunction, defined as at least one of the following markers: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) or alkaline phosphatase above \\>5x upper limit of normality: and\u002For total bilirubin above \\>3x upper limit of normality.\n7. Patients with an ECG with a prolonged QTc interval: QTc greater than 450 msec for men and greater than 470 msec for women.\n8. Patients who are receiving and cannot discontinue the following drugs at least 24 hours prior to randomization: terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine (because of the possibility of QT prolongation), sirolimus, rifampin, rifabutin, carbamazepine, long-acting barbiturates (e.g., phenobarbital, mephobarbital), ritonavir, efavirenz, or ergot alkaloids (e.g., ergotamine, dihydroergotamine).\n9. Serious uncontrolled concomitant disease or comorbidity that, in the opinion of the investigator, may compromise adherence to the study protocol.\n10. Receipt of a prior allogeneic Hematopoietic Cell Transplantation (HCT).\n11. Previous exposure to mold-active prophylaxis (\\>48 hours within 7 days of inclusion).\n12. Patients with relapsed leukemia already included in the trial.\n13. Patient not affiliated to the French social security system\n14. Patient under legal protection (guardianship, curatorship)","ALL","18 Years",{"count":20,"type":21},410,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation strategies for patients with acute myeloid leukemia who receive induction chemotherapy. Allocation strategy based on an invasive mold infection genetic risk will be double-blinded.",[27,28,29,30,31],"Candidiasis","Fungal Infection","Acute Myeloid Leukemia","Genetic Predisposition","Aspergillosis","RECRUITING","2025-12-02",{"date":35,"type":36},"2025-12-09","ACTUAL",{"date":38,"type":36},"2019-02-11",{"date":40,"type":21},"2027-11-30",{"name":42,"class":43},"Bochud Pierre-Yves","OTHER",9,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100599120","isavuconazole-in-critically-ill-patients-efficacy-and-safety-100599120","NCT07080359","Isavuconazole in Critically Ill Patients: Efficacy and Safety","Isavuconazole in Critically Ill Patients: A Study on Antifungal Efficacy and Safety","Inclusion Criteria:\n\n* Adult critically ill patients (≥18 years) admitted to ICU with suspected or confirmed invasive fungal infection (IFI)\n* IFI diagnosis per EORTC\u002FMSGERC 2019 criteria\n\nExclusion Criteria:\n\n* Drug allergy\n* Inherited short QT syndrome\n* Contraindications for nasogastric\u002Foral drug delivery\n* \\\u003C18 years old",{"count":53,"type":21},75,"3 Months","OBSERVATIONAL","Due to factors such as disease status, gastrointestinal conditions, commonly used medications (e.g., vasopressors), and cardiac output, the plasma concentration of isavuconazole in critically ill patients may differ from that in healthy individuals, exhibiting significant variability.\n\nThis study aims to explore the variability of isavuconazole plasma concentrations in critically ill patients and its correlation with efficacy and adverse effects. The research includes:\n\n1. The distribution and variability of isavuconazole plasma concentrations in critically ill patients;\n2. Clinical outcomes;\n3. Adverse effects.",[28,31,58],"Mucormycosis","NOT_YET_RECRUITING","2025-07-14",{"date":62,"type":36},"2025-07-23",{"date":64,"type":21},"2025-08-01",{"date":66,"type":21},"2030-12-31",{"name":68,"class":43},"Shanghai 10th People's Hospital",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":96},"100489444","phase-2-interferon-gamma-as-adjunctive-therapy-in-chronic-pulmonary-aspergillosis-a-randomised-feasibility-study-100489444","NCT05653193","Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study","INCAS","Inclusion Criteria:\n\n* Diagnosis of CPA\n* Started antifungal treatment for CPA within the last 8 weeks and received no antifungals for CPA in the 8 weeks prior\n* Chest CT scan available within the 6 months prior to enrolment\n* Individuals of child bearing potential agree to have pregnancy test an use highly effective contraception\n\nExclusion Criteria:\n\n* Moderate to severe liver dysfunction (Child-Pugh Class B or C)\n* Renal failure (eGFR \\\u003C30 mL\u002Fmin)\n* Clinically diagnosed active depression\n* Active tuberculosis or non-tuberculous mycobacterial (NTM) lung disease\n* Acute infection or other event within the preceding 4 weeks which, as assessed by the investigators, might interfere with the assessment of response to treatment\n* Use of any interferon formulation within the preceding six months\n* Active viral hepatitis infection\n* Pregnancy or breastfeeding\n* Immunosuppression (\\>15mg prednisolone\u002Fday for at least four weeks or equivalent) within the preceding six months\n* Inability to self-administer subcutaneous medications AND lack of a carer who can administer\n* Participants lacking capacity to consent",{"count":77,"type":21},50,[79],"PHASE2","This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients with chronic lung disease like Chronic Obstructive Lung Disease (COPD) or previously treated tuberculosis (TB). It causes gradual destruction of lung tissue by slowly enlarging cavities, frequent secondary infections and poor quality of life. Because of its indolent nature and nonspecific x-ray findings, it often remains unrecognised for years. Around 3600 people live with CPA in the United Kingdom. Mortality from CPA may be up to 40% in five years.\n\nTreatment for CPA relies on antifungals for prolonged periods, but only around 60% of patients improve. It is often long-term or lifelong as the response is slow and some patients experience relapses. In addition, only one class of oral antifungal drugs is licensed for CPA, and they are associated with side effects and high cost. Better treatments are needed for CPA. We do not know why many patients do not respond to treatment. Maybe CPA patients have a weakened immune system and are more susceptible to Aspergillus. Our data suggest that CPA patients produce lower amounts of ΙFNγ, a substance that facilitates the immune system's response against Aspergillus. We have also shown that, when given to patients with CPA who have failed to improve on antifungal treatment, interferon-gamma leads to improvement in important patient-centred outcomes like flares of lung disease or hospital admissions. Interferon-gamma is already in use in the National Health Service of the United Kingdom for other indications. Therefore, its use in CPA should be explored. However, CPA is a rare condition and the tolerability of interferon-gamma is not fully established in these patients. To understand whether a large-scale study is feasible in CPA, we first need preliminary data in smaller numbers of patients.\n\nWe are conducting a randomised trial of interferon-gamma in addition to antifungals in CPA. Patients with CPA starting antifungal treatment are eligible. Participants (25 per group) are randomly assigned to interferon-gamma for 12 weeks (in addition to antifungals) or antifungals only. To test whether the treatment works, we will use measurements of the cavities on chest CT scan and scores on a quality-of-life questionnaire. We will assess for tolerability of treatment at intervals similar to clinical practice. Criteria for progression to the large-scale study will be set based on the proportion of patients willing to participate, and on the proportion who complete the treatment. Data collected on those parameters will allow us to determine the number needed for a definite study.\n\nIf the large-scale study confirms our observations that interferon-gamma improves outcomes in CPA, then treatment duration can be shortened and relapses avoided. In addition, interferon-gamma can then be explored in other chronic lung disease.",[82,31],"Chronic Pulmonary Aspergillosis",[84,85],"immunotherapy","interferon gamma","2025-02-27",{"date":88,"type":36},"2025-03-03",{"date":90,"type":36},"2024-05-17",{"date":92,"type":21},"2026-12",{"name":94,"class":95},"Manchester University NHS Foundation Trust","OTHER_GOV",1]